Injectable Antimicrobial Hydrogel for Extremity Wound Management
Abstract
Effective treatment of war wounds in the forward combat setting and primary care facilities remains a significant challenge facing the military medical community. Battle wounds often necessitate early irrigation, debridement, and antibiotic therapy at the far-forward hospitals. Approximately 20 percent of battlefield wounds are bone fracture and loss at the extremities. However, antibiotic resistance remains a significant problem at primary military medical facilities, occurring in approximately 15 percent of surgical patients. The goal of this study is to developed a single-dose, injectable, prolonged nitric oxide (NO*) hydrogel-delivery system to treat deep wound infection and promote tissue regeneration. We hypotheses that (1) device formulations that release as low as an average of 20 micrometers/h NO* (approximately 6 nmol/h/sq cm) for at least 18 hours will be bactericidal and biocompatible to mammalian cells in vitro and that (2) a total NO* dose of 30 micromole/sq cm in the 5-mm defect will be bactericidal and promote bone regeneration in vivo. The specific aims of the project are to (1) evaluate the NO release, bactericidal efficacy, and biocompatibility of S-nitrosoglutathione (GSNO), short-term delivery microparticle (mSNO-MP), and long-term delivery microparticle (pSNO-MP) devices in vitro and (2) determine the efficacy in clearing infection (bactericidal) and in regenerating bone of hydrogels with GSNO, mSNO-MP, and pSNO-MP donors injected into infected femoral segmental bone defects in rats.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1190465
Entities
People
- Juan M Taboas
Organizations
- University of Pittsburgh